Menu
Back to User profile » Dr Yusuke Okuma
Papers published by Dr Yusuke Okuma:
Alectinib for Miliary Lung Metastasis in ALK-Positive Lung Adenocarcinoma
Satoh H, Okuma Y, Kashima J, Konnno-Yamamoto A, Yatabe Y, Ohe Y
OncoTargets and Therapy 2021, 14:2911-2915
Published Date: 30 April 2021
Ceritinib for an anaplastic lymphoma kinase rearrangement-positive patient previously treated with alectinib with poor performance status
Kitadai R, Okuma Y, Kawai S
OncoTargets and Therapy 2019, 12:15-19
Published Date: 17 December 2018
A patient previously treated with ALK inhibitors for central nervous system lesions from ALK rearranged lung cancer: a case report
Kashima J, Okuma Y, Hishima T
OncoTargets and Therapy 2016, 9:6059-6063
Published Date: 12 October 2016
Noninvasive monitoring of the genetic evolution of EGFR-mutant non-small-cell lung cancer by analyzing circulating tumor DNA during combination chemotherapy with gefitinib and pemetrexed or S-1
Nakahara Y, Takagi Y, Hosomi Y, Kagei A, Yamamoto T, Sawada T, Yomota M, Okuma Y, Mikura S, Okamura T
OncoTargets and Therapy 2016, 9:5287-5295
Published Date: 24 August 2016
Osseous oligometastases from thymic carcinoma: a case report suggesting the effectiveness of palliative-intent radiotherapy treatment
Kashima J, Horio H, Okuma Y, Hosomi Y, Hishima T
OncoTargets and Therapy 2016, 9:1029-1032
Published Date: 29 February 2016
Alectinib for choroidal metastasis in a patient with crizotinib-resistant ALK rearranged positive non-small cell lung cancer
Okuma Y, Tanaka Y, Kamei T, Hosomi Y, Okamura T
OncoTargets and Therapy 2015, 8:1321-1325
Published Date: 3 June 2015
Lung cancer patients harboring epidermal growth factor receptor mutation among those infected by human immunodeficiency virus
Okuma Y, Hosomi Y, Imamura A
OncoTargets and Therapy 2015, 8:111-115
Published Date: 31 December 2014